Bolt Biotherapeutics (NASDAQ: BOLT)
$5.15
(5.3%)
$0.26
Price as of August 22, 2025, 4:00 p.m. ET
Bolt Biotherapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Bolt Biotherapeutics Company Info
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.
News & Analysis
Featured Article
Bolt Revenue Jumps 39 Percent in Q2
Motley Fool Markets Team | Aug 14, 2025
Featured Article
Why Bolt Biotherapeutics Stock Crashed Today
The company announced disappointing interim data from a phase 1/2 study of its lead cancer program.
Keith Speights | Dec 6, 2021
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.